LASP-1 Urine Biomarker for Non-Invasive TCC Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for transitional cell carcinoma (TCC), such as cystoscopy and urine cytology, are invasive, costly, and have low specificity, leading to unnecessary procedures and missed diagnoses, particularly for flat lesions and low-grade tumors, highlighting the need for more sensitive and specific markers.
Innovation Solution
The use of LASP-1 levels in urine samples as a marker for diagnosing and grading TCC, where levels above 1 ng/500µl indicate the presence of TCC and correlate with tumor grade, utilizing specific molecules binding to LASP-1 for detection and quantification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If cystoscopy is used for TCC diagnosis, then diagnostic accuracy is improved, but patient acceptance and ease of operation deteriorate due to invasiveness
Solution Approach 1:
The patent replaces the mechanical invasive procedure of cystoscopy with a biochemical detection method. By measuring LASP-1 protein levels in urine samples using immunoassays or mass spectrometry, the system achieves diagnostic accuracy without requiring physical insertion of instruments into the patient's body, thus eliminating the invasiveness while maintaining diagnostic capability
Solution Approach 2:
The patent introduces LASP-1 as an intermediary biomarker that mediates between the tumor and the diagnostic process. Instead of directly visualizing the tumor through invasive cystoscopy, the method detects LASP-1 protein shed into urine, which serves as an indirect but accurate indicator of TCC presence and severity, thereby avoiding direct invasive contact while preserving diagnostic precision
2Measurement precision
If comprehensive gene microarray analysis is performed, then detection capability is improved, but device complexity and cost increase
Solution Approach 1:
The patent extracts and isolates a single critical biomarker (LASP-1) from the complex panel of genes analyzed in microarray studies. By focusing exclusively on measuring LASP-1 protein levels in urine through simplified immunoassays or mass spectrometry, the method achieves effective TCC detection without requiring complex multi-gene analysis systems, thereby reducing device complexity and cost while maintaining detection capability
Solution Approach 2:
Instead of using a top-down approach with comprehensive gene microarrays that analyze thousands of genes simultaneously, the patent inverts the strategy by bottom-up identification of a single key protein marker. This inverted approach—starting with a specific protein target rather than a broad genetic screen—achieves equivalent or superior diagnostic performance with significantly reduced system complexity and lower cost
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
LASP-1 demonstrates high sensitivity (83.1%) and specificity (85.3%) for TCC detection and grading, reducing false positives and unnecessary procedures, and can complement existing diagnostic methods by providing a more accurate assessment of TCC severity.
Implementation Method 1
utilizing specific molecules binding to LASP-1 for detection and quantification
Data Source
Figure 1A~1H
Figure 2~3
Figure 4~5C
AI summary
The invention relates to the use of LASP-1 in a urine sample obtained from a subject for diagnosing and/or grading transitional cell carcinoma. The invention furthermore relates to a method for diagnosing transitional cell carcinoma comprising detecting the presence or absence of LASP-1 in a urine sample obtained from a subject, wherein the presence of LASP-1 above 1 ng/500mul urine is indicative for transitional cell carcinoma and a method for grading transitional cell carcinoma comprising determining the level of LASP-1 in a urine sample obtained from a subject, wherein the level of LASP-1 correlates with the grade of the transitional cell carcinoma.